SCHEMBL23834451

SCHEMBL23834451

NC(=O)CC1(N)CCC(n2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCK P08631 14/20 0.71
LCK P06239 7/20 0.69
SRC P12931 7/20 0.69
TEK Q02763 7/20 0.69
KDR P35968 3/20 0.69
KDM4E B2RXH2 1/20 0.69
MEN1 O00255 1/20 0.69
RGS12 O14924 1/20 0.69
NPC1 O15118 1/20 0.69
GMNN O75496 1/20 0.69
ALDH1A1 P00352 1/20 0.69
EGFR P00533 1/20 0.69
LMNA P02545 1/20 0.69
TP53 P04637 1/20 0.69
CYP1A2 P05177 1/20 0.69
FYN P06241 1/20 0.69
LYN P07948 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2D6 P10635 1/20 0.69
MAPT P10636 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30053994 1.00 HCK (0.71) HCKLCKSRCTEKKDR
SCHEMBL23834504 0.94 HCK (0.70) HCKLCKSRCTEKKDR
SCHEMBL30143838 0.94 HCK (0.70) HCKLCKSRCTEKKDR
SCHEMBL6461307 0.92 HCK (0.72) HCKLCKSRCTEKKDR
SCHEMBL6461312 0.92 HCK (0.72) HCKLCKSRCTEKKDR
SCHEMBL23834585 0.91 HCK (0.66) HCKLCKSRCTEKKDR
Acetic Acid SCHEMBL6464805 0.90 LCK (0.69) HCKLCKSRCTEKKDR
Acetic Acid SCHEMBL6464807 0.90 LCK (0.69) HCKLCKSRCTEKKDR
Acetic Acid SCHEMBL6465909 0.89 LCK (0.68) HCKLCKSRCTEKKDR
Acetic Acid SCHEMBL6465904 0.89 LCK (0.68) HCKLCKSRCTEKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia FLASH THERAPEUTICS, LLC (US) 2024-04-23 US disclosed
EP-4121430-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA Flash Therapeuttics, LLC (US) 2023-01-25 EP disclosed
CN-115298180-A Compounds for treating or inhibiting recurrence of acute myeloid leukemia 富雷旭医疗有限责任公司 2022-11-04 CN disclosed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 US disclosed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 US disclosed
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 WO disclosed
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia MCL1, FLT3, ABL1 HCK 1658/4885LCK 188/4885SRC 95/4885
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA MCL1, FLT3, ABL1 HCK 1658/4885LCK 188/4885SRC 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.